PainReform Ltd. (NASDAQ:PRFX) Short Interest Up 51.2% in January

PainReform Ltd. (NASDAQ:PRFX) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totaling 101,333 shares, an increase of 51.2% from the December 31st total of 67,001 shares. Currently, 7.7% of the shares of the stock are sold short. Based on an average trading volume of 2,481,511 shares, the days-to-cover ratio is currently 0.0 days. Based on an average trading volume of 2,481,511 shares, the days-to-cover ratio is currently 0.0 days. Currently, 7.7% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PainReform in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

PainReform Stock Down 0.6%

Shares of PRFX traded down $0.00 during mid-day trading on Monday, hitting $0.68. 130,138 shares of the company’s stock traded hands, compared to its average volume of 4,407,153. The firm has a market capitalization of $1.37 million, a P/E ratio of 0.00 and a beta of 0.61. The business’s 50-day moving average price is $0.86 and its 200-day moving average price is $1.17. PainReform has a 1 year low of $0.61 and a 1 year high of $5.47.

PainReform (NASDAQ:PRFX) last released its quarterly earnings results on Wednesday, October 1st. The company reported ($0.55) earnings per share for the quarter.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.